Full-Time

Material Handler II

Confirmed live in the last 24 hours

GeneDx

GeneDx

501-1,000 employees

Provides genetic testing for rare diseases

Compensation Overview

$21.15 - $28.21/hr

Junior, Mid

Gaithersburg, MD, USA

In Person

Category
Inventory Management
Operations & Logistics
Required Skills
Inventory Management
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • High school diploma or GED.
  • 2+ years of warehouse experience (shipping, receiving, inventory control, stockroom functions).
  • Proficient in MS Office (Excel, Word, Outlook).
  • Familiar with computerized Purchasing/Inventory Management/ERP systems.
  • Ability to work in a fast-paced environment.
  • Excellent organizational skills; able to manage multiple tasks.
  • Strong written and verbal communication skills.
Responsibilities
  • Coordinate and manage daily workload with the team.
  • Inspect and process incoming deliveries in ERP system.
  • Record and communicate discrepancies at receipt.
  • Store and preserve inventory, including hazardous materials.
  • Perform inventory counts and monitor supply levels.
  • Transport and store materials throughout the warehouse.
  • Maintain compliance with regulations and internal procedures.
  • Lead continuous improvement activities and support team direction.
Desired Qualifications
  • Experience in healthcare or biotechnology (preferred).
  • Leadership experience (preferred).

GeneDx specializes in genetic testing to identify changes or mutations in a patient's DNA that may be linked to health conditions, particularly rare diseases. The company analyzes DNA samples collected from cheek swabs, blood, or other specimens, and sequences the exomes, which are the parts of the genome that contain genes. This process allows for the detection of genetic variations that can inform diagnosis and treatment. GeneDx differentiates itself from competitors by offering rapid testing services, with products like GenomeXpress and XomeDx Xpress that provide results in as little as seven days, which is crucial for timely medical decisions. The company's goal is to enhance the understanding of genetic disorders for patients, families, and healthcare providers, ultimately improving treatment outcomes and reducing healthcare costs.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Fabric Genomics enhances AI-powered genomic interpretation capabilities.
  • Integration with Epic Aura streamlines genomic testing and improves workflow efficiency.
  • Rapid whole genome sequencing in NICUs reduces diagnostic time and costs.

What critics are saying

  • Integration with Epic Aura may face technical and compatibility challenges.
  • Fabric Genomics acquisition could lead to integration and cultural challenges.
  • Rapid NICU genomic testing may face regulatory scrutiny over accuracy concerns.

What makes GeneDx unique

  • GeneDx excels in rapid and accurate genetic testing services.
  • The company integrates AI with genomic data for enhanced clinical insights.
  • GeneDx's Centrellis platform synthesizes clinical and genomic data effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Employee Discounts

Voluntary benefits

Company News

Business Wire
May 8th, 2025
GeneDx Announces Completion of Fabric Genomics Acquisition

GeneDx (Nasdaq: WGS) today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation.

360Dx
Apr 16th, 2025
GeneDx to Acquire Fabric Genomics in Deal Potentially Worth $51M

NEW YORK - GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.

Hit Consultant
Apr 16th, 2025
Genedx Acquires Fabric Genomics For $33M, Expanding Access To Ai-Powered Genomic Interpretation

What You Should Know:– GeneDx, a company focused on improving health outcomes through genomic insights, has announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation.– The acquisition aims to position GeneDx at the forefront of the next phase of genomic medicine, characterized by decentralized testing with centralized intelligence. Following the closing of the acquisition, Fabric Genomics will initially operate independently while benefiting from GeneDx’s commercial support to accelerate its expansion.AI-Powered Genomic InterpretationThe acquisition is motivated by the increasing accessibility of DNA sequencing, which allows for the decoupling of interpretation services from physical laboratories. This decoupling is expected to provide greater flexibility in integrating genomic information into the workflows of healthcare providers and health systems, both in the U.S. and globally. Fabric Genomics’ platform is known for its ability to scale complex interpretation services and has been used to interpret challenging genetic disease cases for various large health systems, academic centers, and research partners.Through this acquisition, health systems will gain the option to use GeneDx’s centralized lab or conduct sequencing at their own facilities while leveraging GeneDx’s data and Fabric Genomics’ AI-powered interpretation platform. The companies believe that this model will lead to faster and earlier diagnoses of genetic diseases, improved patient outcomes, and reduced costs for healthcare systems.Expanding Market ReachThe acquisition will also enable GeneDx to expand its market reach into several key areas:NICU Genomic Testing: The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants.The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants

Stock Titan
Mar 18th, 2025
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category.

The Chemical Data Company
Mar 13th, 2025
GeneDx to Present Key Research at 2025 ACMG Annual Meeting

GeneDx Showcases Groundbreaking Genomic Research at 2025 ACMG Annual Clinical Genetics Meeting